Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 18/20 | 0.62 |
| ▸ | KCNQ2 | O43526 | 18/20 | 0.62 |
| ▸ | KCNE1 | P15382 | 11/20 | 0.59 |
| ▸ | KCNQ1 | P51787 | 11/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083312 | 0.94 | KCNQ3 (0.64) | KCNQ3KCNQ2KCNE1KCNQ1LMNA | |
| SCHEMBL14083392 | 0.91 | SMN1; SMN2 (0.56) | KCNQ3KCNQ2KCNE1KCNQ1LMNA | |
| SCHEMBL14083110 | 0.90 | KCNQ3 (0.72) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL14083788 | 0.90 | KCNQ3 (0.62) | KCNQ3KCNQ2KCNE1KCNQ1LMNA | |
| SCHEMBL14083379 | 0.89 | TRPV1 (0.55) | KCNQ3KCNQ2KDM4EMEN1MAPT | |
| SCHEMBL14083380 | 0.88 | GRM4 (0.61) | LMNAKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL14083377 | 0.88 | AURKB (0.54) | LMNAKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL14083397 | 0.88 | MAPT (0.47) | KCNQ3KCNQ2LMNAKDM4EMEN1 | |
| SCHEMBL14083384 | 0.87 | TRPV1 (0.55) | KCNQ3KCNQ2KDM4EMEN1MAPT | |
| SCHEMBL14083383 | 0.86 | TRPV1 (0.62) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | KCNQ3 87/4885KCNQ2 67/4885KCNE1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.